Back grey_arrow_rt.gif
Roche has Europe approval for more potent HIV drug
  ZURICH (Reuters) - Roche SA has received European approval for the more potent formulation of its Invirase tablet to treat HIV, the Swiss drugmaker said on Friday.
The European Commission approved the drug in a 500 mg formulation, cutting the daily pill requirement from five to two, Roche said in a statement.
Invirase 500 mg received U.S. Food and Drug Administration (FDA) approval last December.
In February, a panel of European experts had already backed the more potent formulation the drug.
Earlier this month, Roche said it would withdraw its older anti-HIV drug Fortovase in early 2006 because demand for the drug has declined significantly.
Invirase, which is not among the Swiss drugmaker's top 20 products, was launched in 1995 and was the first HIV protease inhibitor on the market.
  icon paper stack View Older Articles   Back to Top